Clarity Pharmaceuticals (CU6) - Lesion Size: A New Potential Differentiator
Clarity have released further data from their Phase II COBRA trial evaluating their 64Cu-SAR- bisPSMA PET diagnostic agent in suspected biochemical...
342 Views
Clarity Pharmaceuticals (CU6) - The COBRA Strikes…with a Lot of Venom
Clarity have released results from their Phase II COBRA trial, evaluating their 64Cu-SAR-bisPSMA PET agent in prostate cancer (PCa) patients with...
341 Views
Clarity Pharmaceuticals (CU6) - Therapeutically Driven
We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $2.78/sh (unrisked $7.41/sh).
324 Views
Clarity Pharmaceuticals (CU6) - Copper Takes a Bigger Chunk of the Pie
We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $2.13/sh (unrisked $5.15/sh).
412 Views
Clarity Pharmaceuticals (CU6) - Copper Firing: PSMA Tx and Dx Updates
Clarity have announced additional data from their Phase I/IIa SECuRE trial in metastatic castrate resistant prostate cancer (mCRPC).
225 Views